IceCure Medical Ltd (ICCM)
1.11
0.01 (0.45%)
At close: Mar 28, 2025, 3:59 PM
1.12
0.72%
After-hours: Mar 28, 2025, 05:40 PM EDT
0.45% (1D)
| Bid | 1.05 |
| Market Cap | 63.07M |
| Revenue (ttm) | 4.47M |
| Net Income (ttm) | -16.72M |
| EPS (ttm) | -0.28 |
| PE Ratio (ttm) | -3.98 |
| Forward PE | -5.02 |
| Analyst | Buy |
| Ask | 1.18 |
| Volume | 220,547 |
| Avg. Volume (20D) | 383,275 |
| Open | 1.09 |
| Previous Close | 1.10 |
| Day's Range | 1.06 - 1.15 |
| 52-Week Range | 0.48 - 1.66 |
| Beta | 2.42 |
About ICCM
IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel....
Industry Medical - Devices
Sector Healthcare
IPO Date Aug 26, 2021
Employees 71
Stock Exchange NASDAQ
Ticker Symbol ICCM
Website https://www.icecure-medical.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ICCM stock is "Buy." The 12-month stock price forecast is $2.5, which is an increase of 124.22% from the latest price.
Stock ForecastsEarnings Surprise
IceCure Medical Ltd has released their quartely earnings
on Mar 27, 2025:
Next Earnings Release
IceCure Medical Ltd is scheduled to release its earnings on May 27, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
-15.54%
IceCure Medical shares are trading lower. The comp...
Unlock content with
Pro Subscription
5 months ago
+18.18%
IceCure Medical shares are trading higher after the company announced that a large number of public comments have been posted from key stakeholders ahead of the FDA Medical Device Advisory Committee Panel for marketing authorization of ProSens® cryoablation in early-stage low risk breast cancer.
